Top

Environmental Health and Preventive Medicine

Published in:

01-03-2008 | Special Feature

Immunological alterations found in mesothelioma patients and supporting experimental evidence

Authors: Yoshie Miura, Yasumitsu Nishimura, Megumi Maeda, Shuko Murakami, Hiroaki Hayashi, Kazuya Fukuoka, Takumi Kishimoto, Takashi Nakano, Takemi Otsuki

Published in: Environmental Health and Preventive Medicine | Issue 2/2008

Abstract

It is common knowledge that exposure to asbestos causes asbestos-related diseases, such as asbestosis, lung cancer and malignant mesothelioma, not only in people who have had long-term contact with asbestos in their work environment but also in residents living near factories that handle asbestos. Since the summer of 2005, these revelations turned into a large medical problem and caused and social unrest. We have focused on the immunological effects of both asbestos and silica on the human immune system. In this brief review, we introduce immunological alterations found in patients with malignant mesothelioma and describe the experimental background in which these were found. Analyzing the immunological effects of asbestos may improve our understanding of the biological effects of asbestos.

Becklake MR, Bagatin E, Neder JA. Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century. Int J Tuberc Lung Dis. 2007;11:356–69.PubMed

O’Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ. Asbestos-related lung disease. Am Fam Physician. 2007;75:683–8.PubMed

Niklinski J, Niklinska W, Chyczewska E, Laudanski J, Naumnik W, Chyczewski L, Pluygers E. The epidemiology of asbestos-related diseases. Lung Cancer. 2004;Suppl 1:S7–15.CrossRef

Cooper GS, Parks CG. Occupational and environmental exposures as risk factors for systemic lupus erythematosus. Curr Rheumatol Rep. 2004;6:367–74.PubMedCrossRef

Hess EV. Environmental chemicals and autoimmune disease: cause and effect. Toxicology. 2002;181–182:65–70.PubMedCrossRef

Cooper GS, Miller FW, Germolec DR. Occupational exposures and autoimmune diseases. Int Immunopharmacol. 2002;2(2–3):303–13.PubMedCrossRef

Caplan A. Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax. 1953;8(1):29–37.PubMedCrossRef

Caplan A, Cowen ED, Gough J. Rheumatoid pneumoconiosis in a foundry worker. Thorax. 1958;13:181–4.PubMed

Caplan A. Rheumatoid disease and pneumoconiosis (Caplan’s syndrome). Proc R Soc Med. 1959;52:1111–3.PubMed

10.

Shons AR, Schubert W. Silicone breast implants and immune disease. Ann Plast Surg. 1992;28:491–9.PubMedCrossRef

11.

Hirmand H, Latrenta GS, Hoffman LA. Autoimmune disease and silicone breast implants. Oncology (Williston Park). 1993;7:17–24.

12.

Brown SL, Langone JJ, Brinton LA. Silicone breast implants and autoimmune disease. J Am Med Womens Assoc. 1998;53:21–24, 40.PubMed

13.

Harington JS. The carcinogenicity of chrysotile asbestos. Ann N Y Acad Sci. 1991;643:465–72.PubMedCrossRef

14.

Fattman CL, Chu CT, Oury TD. Experimental models of asbestos-related diseases. In: Roggli VL, Oury TM, Sporn TA, editors. Asbestos-associated diseases. New York: Springer Science + Business Media; 2004. p. 256–308.

15.

Lemen RA. Epidermiology of asbestos-related diseases and the knowledge that led to what is known today. In: Dodson RF, Hammar SP, editors. Asbestos: risk assessment, epidemiology, and health effects. Boca Raton, FL: CRC; 2006. p. 201–308.

16.

Miura Y, Nishimura Y, Katsuyama H, Maeda M, Hayashi H, Dong M, Hyodoh F et al. Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells. Apoptosis. 2006;11:1825–35.PubMedCrossRef

17.

Hyodoh F, Takata-Tomokuni A, Miura Y, Sakaguchi H, Hatayama T, Hatada S, Katsuyama H et al. Inhibitory effects of anti-oxidants on apoptosis of a human polyclonal T-cell line, MT-2, induced by an asbestos, chrysotile-A. Scand J Immunol. 2005;61:442–8.PubMedCrossRef

18.

Gerwin BI, Lechner JF, Reddel RR, Roberts AB, Robbins KC, Gabrielson EW, Harris CC. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 1987;47:6180–4.PubMed

19.

Versnel MA, Bouts MJ, Langerak AW, van der Kwast TH, Hoogsteden HC, Hagemeijer A, Heldin CH. Hydrocortisone-induced increase of PDGF beta-receptor expression in a human malignant mesothelioma cell line. Exp Cell Res. 1992;200:83–8.PubMedCrossRef

20.

Klominek J, Baskin B, Hauzenberger D. Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin Exp Metastasis. 1998;16:529–39.PubMedCrossRef

21.

Langerak AW, De Laat PA, Van Der Linden-Van Beurden CA, Delahaye M, Van Der Kwast TH, Hoogsteden HC, Benner R et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol. 1996;178:151–60.PubMedCrossRef

22.

Aikoh T, Tomokuni A, Matsukii T, Hyodoh F, Ueki H, Otsuki T, Ueki A. Activation-induced cell death in human peripheral blood lymphocytes after stimulation with silicate in vitro. Int J Oncol. 1998;12:1355–9.PubMed

23.

Ueki A. Biological effects of asbestos fibers on human cells in vitro-especially on lymphovytes and neutrophils. Indust Health. 2001;39:84–93.CrossRef

24.

Ueki A, Nakashima M, Kishimoto T, Nakamura J, Kinugawa K, Sakaguchi H. Analysis of the expression of TcR Vβ peretoires in patients with silicosis. J Occup Health. 1996;38:67–70.CrossRef

25.

Schubert MS. A superantigen hypothesis for the pathogenesis of chronic hypertrophic rhinosinusitis, allergic fungal sinusitis, and related disorders. Ann Allergy Asthma Immunol. 2001;87:181–8.PubMedCrossRef

26.

Li H, Llera A, Malchiodi EL, Mariuzza RA. The structural basis of T cell activation by superantigens. Annu Rev Immunol. 1999;17:435–66.PubMedCrossRef

27.

Torres BA, Johnson HM. Modulation of disease by superantigens. Curr Opin Immunol. 1998;10:465–70.PubMedCrossRef

28.

Sumida T, Matsumoto I, Maeda T, Nishioka K. T-cell receptor in Sjogren’s syndrome. Br J Rheumatol. 1997;36:622–9. Review.PubMedCrossRef

29.

Nishimura Y, Miura Y, Maeda M, Hayashi H, Dong M, Katsuyama H, Tomita M et al. Expression of the T cell receptor Vbeta repertoire in a human T cell resistant to asbestos-induced apoptosis and peripheral blood T cells from patients with silica and asbestos-related diseases. Int J Immunopathol Pharmacol. 2006;19:795–805.PubMed

30.

Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, Albelda SM. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res. 2004;10:5907–18.PubMedCrossRef

31.

Kuwahara M, Takeda M, Takeuchi Y, Kuwahara M, Harada T, Maita K. Transforming growth factor beta production by spontaneous malignant mesothelioma cell lines derived from Fisher 344 rats. Virchows Arch. 2001;438:492–7.PubMedCrossRef

32.

Maeda J, Ueki N, Ohkawa T, Iwahashi N, Nakano T, Hada T, Higashino K. Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer. Clin Exp Immunol. 1994;98:319–22.PubMedCrossRef

33.

Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BW. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors. 1994;11:29–44.PubMedCrossRef

Title: Immunological alterations found in mesothelioma patients and supporting experimental evidence
Authors: Yoshie Miura
Yasumitsu Nishimura
Megumi Maeda
Shuko Murakami
Hiroaki Hayashi
Kazuya Fukuoka
Takumi Kishimoto
Takashi Nakano
Takemi Otsuki
Publication date: 01-03-2008
Publisher: Springer Japan
Published in: Environmental Health and Preventive Medicine / Issue 2/2008
Print ISSN: 1342-078X
Electronic ISSN: 1347-4715
DOI: https://doi.org/10.1007/s12199-007-0012-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Immunological alterations found in mesothelioma patients and supporting experimental evidence

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Asbestos and malignant mesothelioma: foreword

Selenium: its role as antioxidant in human health

Air pollution and population health: a global challenge

Current therapies for malignant pleural mesothelioma

Pathology of mesothelioma

Molecular biology of malignant mesothelioma